People Can Call Toll Free 1- (800) YAZ-0287 if They Took Yaz, Yasmin, BeYaz or Ocella and Suffered Pulmonary Embolisms, DVT’s or Stroke; Cases are Now Settling
Women Injured by YAZ, YASMIN, OCELLA or BEYAZ May be Eligible to Participate in the YAZ Settlement Blau, Brown & Leonard, LLC, pioneers in birth control litigation, have set up a new hotline at (800) YAZ-0287 to field calls about blood clot injuries from Yaz, Yasmin, Ocella or Beyaz. Individuals who have questions of whether they are eligible to participate in a settlement can call toll free 24/7 to (800) 929-0287 to receive a free, confidential consultation.
New York, NY (PRWEB) September 02, 2012
Blau, Brown & Leonard, LLC, pioneers in birth control litigation, have set up a new hotline at (800) YAZ-0287 to field calls about blood clot injuries from Yaz, Yasmin, Ocella or Beyaz. Individuals who have questions of whether they are eligible to participate in a settlement can call toll free 24/7 to (800) 929-0287 to receive a free, confidential consultation.
Bayer, the makers of YAZ, YASMIN, OCELLA and BEYAZ are settling cases of women who sustained blood clot injuries from their birth control. Women who suffered from a DVT, PE, Stroke, Heart Attack or Death, may be able to participate. Depending on when the injury occurred and in what state the woman resided at the time, and in what state it was prescribed may effect ones rights.
Medical records need to be gathered in a timely manner and the case must be put into suit promptly to protect the rights of the woman or else the right to recovery may be barred by the Statute of Limitations. Lawyers are standing by at (800) YAZ-0287 to field questions about the settlement, how to participate, and whether an individual may be entitled to compensation.
The signature injury that Bayer is including in the settlement at this point are blood clot related injuries. Blood clots are the thickening of the blood within the body causing restricted blood flow in an area and a potentially life threatening situation. All hormonal birth control can cause blood clots, but according to the FDA, the fourth generation hormone known as drospirenone in Yaz, Yasmin, Beyaz and Ocella, have been shown to have an elevated risk of clotting events. Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), strokes, and heart attacks may all be linked to blood clots from Yaz, Yasmin, Beyaz and Ocella. The Yaz lawsuit is consolidated into an MDL – docket number MDL 2100 in Illinois (http://www.ilsd.uscourts.gov/mdl/mdl2100.aspx) and as a mass tort in New Jersey State Courts.
Recent FDA Warning – Label Change
After years of scrutiny, on April 10, 2012 the FDA commanded that Bayer change their label to unequivocally state the increased risk of blood clots with the products Yasmin, Yaz, Beyaz and Ocella, all containing drospirenone. Attorney Jason T. Brown, part of Blau, Brown & Leonard’s trial team stated, “The label change is a start, but this product needs to be off the market. Other than the profits of the drug manufacturers, there is no reason for this alien substance drospirenone to be put into womens’ bodies when earlier hormones were much safer. Shame on Bayer for putting their profits over the health and well being of our mothers, daughters, sisters and friends.”
About Blau, Brown & Leonard, LLC
Blau, Brown & Leonard, LLC is a law firm representing women nationwide who have been injured by Yaz, Yasmin, Ocella or BeYaz. The firm has a toll free number dedicated to educating women about their rights in this litigation at (800) YAZ-0287. Blau, Brown & Leonard, LLC is a formidable team of trial attorneys who have experience working mass torts and many million dollar settlements and judgments on behalf of their clients. Managing Partner Jason T. Brown was a former Special Agent and Legal Adviser to the Federal Bureau of Investigation (FBI) and is lead counsel in class actions all over the country. Often times, Mr. Brown will field calls and questions directly. There is no fee unless the firm is successful with the case.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9859485.htm